Definium Therapeutics (DFTX) Free Cash Flow (2019 - 2026)
Definium Therapeutics (DFTX) reported Free Cash Flow of -$42.6 million for Q1 2026, down 44.91% year-over-year from -$77.4 million in Q1 2025, and up 0.8% on a QoQ basis from -$43.0 million in Q4 2025.
Definium Therapeutics (DFTX) has 8 years of Free Cash Flow data on file, last reported at -$42.6 million in Q1 2026.
- Quarterly Free Cash Flow fell 44.91% year-over-year to -$42.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$144.8 million (down 57.45% YoY) and the FY2025 annual result came in at -$131.6 million, down 66.26% from the prior year.
- Free Cash Flow rose to -$42.6 million in Q1 2026 per DFTX's latest filing, from -$43.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$9.3 million in Q3 2022 and bottomed at -$43.0 million in Q4 2025.
- The 5-year median for Free Cash Flow is -$17.2 million (2024), against an average of -$21.6 million.
- The widest annual swing landed in 2022, when Free Cash Flow soared 44.6%; it then tumbled 78.83% in 2023.
- Tracing DFTX's Free Cash Flow over 5 years: stood at -$12.8 million in 2022, then tumbled by 60.04% to -$20.6 million in 2023, then declined by 23.28% to -$25.4 million in 2024, then tumbled by 69.52% to -$43.0 million in 2025, then advanced by 0.8% to -$42.6 million in 2026.
- Per Business Quant, the three latest DFTX Free Cash Flow figures stand at -$42.6 million (Q1 2026), -$43.0 million (Q4 2025), and -$29.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | -42.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.63 Mn |
| Mar 31, 2026 | -42.63 Mn |
| Dec 31, 2025 | -42.98 Mn |
| Dec 31, 2025 | -42.98 Mn |
| Sep 30, 2025 | -29.57 Mn |
| Sep 30, 2025 | -29.57 Mn |
| Jun 30, 2025 | -29.60 Mn |
| Jun 30, 2025 | -29.60 Mn |
| Mar 31, 2025 | -29.42 Mn |
| Mar 31, 2025 | -29.42 Mn |
| Dec 31, 2024 | -25.35 Mn |
| Dec 31, 2024 | -25.35 Mn |
| Sep 30, 2024 | -17.19 Mn |
| Sep 30, 2024 | -17.19 Mn |
| Jun 30, 2024 | -19.99 Mn |
| Jun 30, 2024 | -19.99 Mn |
| Mar 31, 2024 | -16.60 Mn |
| Mar 31, 2024 | -16.60 Mn |
| Dec 31, 2023 | -20.56 Mn |
| Dec 31, 2023 | -20.56 Mn |
| Sep 30, 2023 | -16.63 Mn |
| Sep 30, 2023 | -16.63 Mn |
| Jun 30, 2023 | -13.85 Mn |
| Jun 30, 2023 | -13.85 Mn |
| Mar 31, 2023 | -13.33 Mn |
| Mar 31, 2023 | -13.33 Mn |
| Dec 31, 2022 | -12.85 Mn |
| Dec 31, 2022 | -12.85 Mn |
| Sep 30, 2022 | -9.30 Mn |
| Sep 30, 2022 | -9.30 Mn |
| Jun 30, 2022 | -15.13 Mn |
| Jun 30, 2022 | -15.13 Mn |
| Mar 31, 2022 | -12.87 Mn |
| Mar 31, 2022 | -12.87 Mn |
| Dec 31, 2021 | -7.83 Mn |
| Dec 31, 2021 | -7.83 Mn |
| Sep 30, 2021 | -16.78 Mn |
| Sep 30, 2021 | -16.78 Mn |
| Jun 30, 2021 | -11.17 Mn |
| Jun 30, 2021 | -11.17 Mn |
| Mar 31, 2021 | -10.04 Mn |
| Mar 31, 2021 | -10.04 Mn |
| Dec 31, 2020 | -7.14 Mn |
| Dec 31, 2020 | -7.14 Mn |
| Sep 30, 2020 | -5.80 Mn |
| Sep 30, 2020 | -5.80 Mn |
| Jun 30, 2020 | -5.55 Mn |
| Jun 30, 2020 | -5.55 Mn |
| Mar 31, 2020 | -5.10 Mn |
| Mar 31, 2020 | -5.10 Mn |
| Dec 31, 2019 | -3.20 Mn |
| Dec 31, 2019 | -3.20 Mn |